The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species
mBio · 2024
DOI: 10.1128/mbio.02502-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Jana Nysten und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Riboflavin, Antifungal Agents, Biosynthetic Pathways, Candidiasis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek (FWO), Onderzoeksraad, KU Leuven (Research Council, KU Leuven).
Abstract (Originalsprache)
In recent decades, there has been an increase in the occurrence of fungal infections; yet, the arsenal of drugs available to fight invasive infections remains very limited. The development of new antifungal agents is hindered by the restricted number of molecular targets that can be exploited, given the shared eukaryotic nature of fungi and their hosts which often leads to host toxicity. In this paper, we examine the riboflavin biosynthetic pathway as a potential novel drug target. Riboflavin is an essential nutrient for all living organisms. Its biosynthetic pathway does not exist in humans, who obtain riboflavin through their diet. Our findings demonstrate that all enzymes in the pathway are essential for Candida albicans , Candida glabrata, and Saccharomyces cerevisiae. Auxotrophic strains, which mimic a drug targeting the biosynthesis pathway, experience rapid mortality in the absence of supplemented riboflavin. Furthermore, RIB1 is essential for virulence in both C. albicans and C. glabrata in a systemic mouse model. The fungal burden of a RIB1 deletion strain is significantly reduced in the kidneys and brain of infected mice, and this reduction becomes more pronounced over time. Nevertheless, auxotrophic cells can still take up external riboflavin when supplemented. We identified Orf19.4337 as the riboflavin importer in C. albicans and named it Rut1. We found that Rut1 only facilitates growth at external riboflavin concentrations that exceed the physiological concentrations in the human body. This suggests that riboflavin uptake is unlikely to serve as a resistance mechanism against drugs targeting the biosynthesis pathway. Interestingly, the uptake system in S. cerevisiae is more effective than in C. albicans and C. glabrata, enabling an auxotrophic S. cerevisiae strain to outcompete an auxotrophic C. albicans strain in lower riboflavin concentrations. IMPORTANCE Candida species are a common cause of invasive fungal infections. Candida albicans , in particular, poses a significant threat to immunocompromised individuals. This opportunistic pathogen typically lives as a commensal on mucosal surfaces of healthy individuals but it can also cause invasive infections associated with high morbidity and mortality. Currently, there are only three major classes of antifungal drugs available to treat these infections. In addition, the efficacy of these antifungal agents is restricted by host toxicity, suboptimal pharmacokinetics, a narrow spectrum of activity, intrinsic resistance of fungal species, such as Candida glabrata , to certain drugs, and the acquisition of resistance over time. Therefore, it is crucial to identify new antifungal drug targets with novel modes of action to add to the limited armamentarium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.
ORCID-Profile: Jana Nysten, Patrick Van Dijck
Förderung
- Fonds Wetenschappelijk Onderzoek (FWO)
- Onderzoeksraad, KU Leuven (Research Council, KU Leuven)
Zitieren
APA
Nysten, J., Peetermans, A., Vaneynde, D., Jacobs, S., Demuyser, L., & Van Dijck, P. (2024). The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species. mBio. https://doi.org/10.1128/mbio.02502-24
Vancouver
Nysten J, Peetermans A, Vaneynde D, Jacobs S, Demuyser L, Van Dijck P. The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species. mBio. 2024. doi:10.1128/mbio.02502-24
BibTeX
@article{Nysten2024,
author = {Nysten, Jana and Peetermans, Arne and Vaneynde, Dries and Jacobs, Stef and Demuyser, Liesbeth and Van Dijck, Patrick},
title = {The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.02502-24}
}
EUVIMED